梦境强化

梦境强化 (Dream potentiation)

◀返回

梦境强化被定义为一种增加睡眠中梦境状态的主观强度、生动性和频率的效应哦[1][2]。这种效应还会导致梦境的情节更加复杂和不连贯，并且具有更高的细节水平和清晰度呢[2]。此外，这种效应会大大增加做清醒梦的可能性。

梦境强化最常在中等剂量的促梦化合物影响下被诱发，这是一类在睡前服用专门用于强化梦境的致幻剂。不过嘛，它也可能作为在极多种类物质影响下入睡后的残留副作用出现。在其他时候，它可能作为一种相对持久的效应出现，是致幻剂持久性知觉障碍 (HPPD) 的症状之一哦。

分析

有数百项研究将拟胆碱药局部或系统地应用于桥脑网状结构内侧以诱导和强化REM睡眠的产生[3]。一些胆碱能药物诱导REM睡眠，而另一些则强化REM睡眠[2][4][5][6][7]。然而，关于这种效应是否仅限于抑郁症患者，证据还存在冲突呢[6][7][8][9]。胺类药物，如血清素和/或去甲肾上腺素再摄取抑制类抗抑郁药，会抑制REM睡眠[2][10][11]。非抗抑郁药，包括苯丙胺类、巴比妥类和麻醉剂，并没有显示出REM睡眠的大幅和持续减少随后出现反弹的现象[12]。

体验报告

在我们的体验报告中，描述了这种效应的轶事报告包括：

• Experience:225mg Pregabalin +Cannabis -Bliss and Serenity; a hedonistic evening
• Experience:25mg Quetiapine - Nice buzz
• Experience:3-MEO-PCMo (420mg) - Trip Report_-_Trip_Report)
• Experience:DXM 1200mg - A calm flood.

另见

• 负责任的用药索引页
• 清醒梦
• 促梦剂
• 主观效应索引
• 梦境抑制
• 解离剂 - 主观效应
• 迷幻剂 - 主观效应
• 谵妄剂 - 主观效应

外部链接

• 梦 (维基百科)
• 促梦剂 (维基百科)
• 药物与梦境

参考文献

1. ↑ Pavel, S.; Goldstein, R.; Petrescu, Magdalena (1980). "Vasotocin, melatonin and narcolepsy: Possible involvement of the pineal gland in its patho-physiological mechanism". Peptides. 1 (4): 281–284. doi:10.1016/0196-9781(80)90003-0. ISSN 0196-9781.
2. ↑ 2.0 2.1 2.2 2.3 Pace-Schott, Edward F.; Gersh, Tamara; Silvestri, Rosalia; Stickgold, Robert; Salzman, Carl; Hobson, J. Allan (2001). "SSRI Treatment suppresses dream recall frequency but increases subjective dream intensity in normal subjects". Journal of Sleep Research. 10 (2): 129–142. doi:10.1046/j.1365-2869.2001.00249.x. ISSN 0962-1105.
3. ↑ Kubin, L. (February 2001). "Carbachol models of REM sleep: recent developments and new directions". Archives Italiennes De Biologie. 139 (1–2): 147–168. ISSN 0003-9829.
4. ↑ Berger, Mathias; Riemann, Dieter (1993). "REM sleep in depression-an overview". Journal of Sleep Research. 2 (4): 211–223. doi:10.1111/j.1365-2869.1993.tb00092.x. ISSN 0962-1105.
5. ↑ Sitaram, N.; Moore, Angela M.; Gillin, J. Christian (1978). "Experimental acceleration and slowing of REM sleep ultradian rhythm by cholinergic agonist and antagonist". Nature. 274 (5670): 490–492. doi:10.1038/274490a0. ISSN 0028-0836.
6. ↑ 6.0 6.1 Sitaram, Natraj (1978). "The Effect of Physostigmine on Normal Human Sleep and Dreaming". Archives of General Psychiatry. 35 (10): 1239. doi:10.1001/archpsyc.1978.01770340089010. ISSN 0003-990X.
7. ↑ 7.0 7.1 Sitaram, N; Wyatt, R.; Dawson, S; Gillin, J. (1976). "REM sleep induction by physostigmine infusion during sleep". Science. 191 (4233): 1281–1283. doi:10.1126/science.176724. ISSN 0036-8075.
8. ↑ Berger, Mathias (1989). "The Cholinergic Rapid Eye Movement Sleep Induction Test With RS-86". Archives of General Psychiatry. 46 (5): 421. doi:10.1001/archpsyc.1989.01810050035006. ISSN 0003-990X.
9. ↑ Lauriello, John; Kenny, William M.; Sutton, Laura; Golshan, Shahrokh; Ruiz, Caroline; Kelsoe, John; Rapaport, Mark; Christian Gillin, J. (1993). "The cholinergic REM sleep induction test with pilocarpine in mildly depressed patients and normal controls". Biological Psychiatry. 33 (1): 33–39. doi:10.1016/0006-3223(93)90275-I. ISSN 0006-3223.
10. ↑ Sharpley, Ann L.; Cowen, Philip J. (1995). "Effect of pharmacologic treatments on the sleep of depressed patients". Biological Psychiatry. 37 (2): 85–98. doi:10.1016/0006-3223(94)00135-P. ISSN 0006-3223.
11. ↑ Trivedi, M (1999). "Effects of Fluoxetine on the Polysomnogram in Outpatients with Major Depression". Neuropsychopharmacology. 20 (5): 447–459. doi:10.1016/S0893-133X(98)00131-6. ISSN 0893-133X.
12. ↑ Vogel, G.W.; Buffenstein, A.; Minter, K.; Hennessey, Ann (1990). "Drug effects on REM sleep and on endogenous depression". Neuroscience & Biobehavioral Reviews. 14 (1): 49–63. doi:10.1016/S0149-7634(05)80159-9. ISSN 0149-7634.